BIOCON LTD. - 532523 - Board Meeting Outcome for Outcome Of Board Meeting
Financial Results for quarter ended December 31, 202120-01-2022
20-01-2022
Biocon share price surges after Morgan Stanley upgrades stock to 'outperform'
The brokerage raised its price target by 25 percent to Rs 465, saying the pharma company's earnings may have reached a point of inflection after three years of single-digit profit growth19-01-2022
COVID-19: Would like to give booster doses to all employees', says Kiran Mazumdar-Shaw
Founder and executive chairperson of Biocon Kiran Mazumdar Shaw has said that as an employer she would want to deliver booster doses to all Biocon employees due to the surge in coronavirus cases.18-01-2022
BIOCON LTD. - 532523 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021.12-01-2022
BIOCON LTD. - 532523 - Shareholding for the Period Ended December 31, 2021
Biocon Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here11-01-2022
BIOCON LTD. - 532523 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 115160 Name of the Signatory :- Mayank VermaDesignation :- Company Secretary and Compliance Officer10-01-2022
USFDA rejects Biocon, Viatris application for Insulin Aspart
The company will respond to the CRL to satisfy the FDA's requests08-01-2022
BIOCON LTD. - 532523 - Company Statement
'The U.S. FDA has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for Insulin Aspart filed by our partner Viatris (Mylan). We will respond to the CRL to satisfy the FDA's requests. The CRL did not identify any outstanding scientific issues with the product.' - Company Spokesperson, Biocon Biologics.07-01-2022
Biocon announces merger of its arm with Serum Institute subsidiary
The company stated that there is no cash consideration involved but BBL will issue and allot 15 per cent equity shares to Serum on a fully diluted basis, subject to necessary approvals and sanctions.04-01-2022
BIOCON LTD. - 532523 - Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
This is in continuation to our intimation dated September 16, 2021, with regard to merger of Covidshield Technologies Private Limited ('CTPL' or the 'Transferor Company'), a wholly-owned subsidiary of Serum Institute Life Sciences Private Limited ('SILS'), with, and into Biocon Biologics Limited ('BBL' or the 'Transferee Company'), a material subsidiary of Biocon Limited ('the Company'). We would like to inform that the Board of Directors of BBL at its meeting held today i.e., January 3, 2022, has approved the scheme of Merger by Absorption ('Scheme') pursuant to Section 230 to 232 of the Companies Act, 2013 for the said merger as mentioned above. The scheme is subject to the requisite statutory approvals including approval of the National Company Law Tribunal ('NCLT') and/ or such other competent authorities (including the Competition Commission of India), and the shareholders and creditors of the Transferor Company and the Transferee Company.03-01-2022